Trevi Therapeutics, Inc. $TRVI Shares Sold by Pictet Asset Management Holding SA

Posted by George Bondi on Nov 12th, 2026

Pictet Asset Management Holding SA cut its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 3.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,951,394 shares of the company’s stock after selling 62,392 shares during the quarter. Pictet Asset Management Holding SA owned approximately 1.37% of Trevi Therapeutics worth $27,944,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Oppenheimer & Co. Inc. increased its stake in Trevi Therapeutics by 0.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 100,696 shares of the company’s stock valued at $1,442,000 after buying an additional 925 shares during the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Trevi Therapeutics by 4.3% during the 3rd quarter. AlphaCentric Advisors LLC now owns 25,370 shares of the company’s stock worth $363,000 after buying an additional 1,053 shares in the last quarter. KBC Group NV bought a new position in shares of Trevi Therapeutics during the 1st quarter worth approximately $29,000. Arizona State Retirement System lifted its position in shares of Trevi Therapeutics by 12.9% during the 2nd quarter. Arizona State Retirement System now owns 26,434 shares of the company’s stock worth $493,000 after buying an additional 3,019 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its position in shares of Trevi Therapeutics by 848.7% during the 3rd quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock worth $51,000 after buying an additional 3,191 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Michael Heffernan sold 39,473 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the sale, the director owned 6,351 shares in the company, valued at $95,836.59. This trade represents a 86.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.39% of the stock is currently owned by insiders.

Trevi Therapeutics Stock Performance

TRVI opened at $14.81 on Thursday. Trevi Therapeutics, Inc. has a fifty-two week low of $9.82 and a fifty-two week high of $20.22. The firm has a 50-day moving average of $14.17 and a 200 day moving average of $14.46. The firm has a market cap of $2.11 billion, a P/E ratio of -37.97 and a beta of 1.15.

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). Equities research analysts predict that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on TRVI. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $40.00 target price on shares of Trevi Therapeutics in a report on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $23.00 price target on shares of Trevi Therapeutics in a research report on Friday, August 7th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Thursday, October 15th. Finally, B. Riley Financial upped their price objective on Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Trevi Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $27.08.

Check Out Our Latest Stock Report on Trevi Therapeutics

Trevi Therapeutics Company Profile

(Free Report)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.